Search
Suvecaltamide
go.drugbank.com/drugs/DB19139InvestigationalSuvecaltamide is under investigation in clinical trial NCT05122650 (A Study to Assess the Safety and Efficacy of JZP385 in the Treatment of Adults With Moderate to Severe Essential Tremor (ET)).
Recombinant stabilized RSV A prefusion F antigen
go.drugbank.com/drugs/DB18713ApprovedInvestigational[L49555] Abrysvo was approved for the same indications in the EU in August 2023[L49565] and Canada in December 2023.
Vismodegib
go.drugbank.com/drugs/DB08828ApprovedInvestigationalIn July 2013, it was approved by the EMA, and since then, it has been approved by several other countries.[A7370,A258618,L45803]
Mirabegron
go.drugbank.com/drugs/DB08893ApprovedInvestigational[L32853] Mirabegron is also used in other jurisdictions across the globe, including Canada,[L32925] the EU,[L32945] and Japan.[A7469] … Mirabegron has a comparatively favorable adverse effect profile as compared to other available treatment options, and its complementary mechanism to the antimuscarinics that came before it allows for its
Oveporexton
go.drugbank.com/drugs/DB21680ApprovedL64068] NT1 is caused by the loss of orexin neuropeptide signaling, and oveporexton works by selectively activating OX2R to restore this signaling, promoting wakefulness and reducing cataplexy and other REM-sleep-related
Ritlecitinib
go.drugbank.com/drugs/DB14924ApprovedInvestigational[L47092,L47127] It was further approved by the EMA in September 2023.[L48181] Ritlecitinib is administered orally and is the first member of its class.
Nitrilotriacetic acid
go.drugbank.com/drugs/DB03040Experimental(From Miall's Dictionary of Chemistry, 5th ed.)
Methotrexate
go.drugbank.com/drugs/DB00563ApprovedInvestigationalMethotrexate is a folate derivative that inhibits several enzymes responsible for nucleotide synthesis. This inhibition leads to suppression of inflammation as well as prevention of cell division. Because of these effects, methotrexate i...
Products: NORDIMET 10MG ILO I E FER, NORDIMET 15MG ILO I E FERTuspetinib
go.drugbank.com/drugs/DB15343InvestigationalTuspetinib (HM-43239) is under investigation in clinical trial NCT03850574 (Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HM43239 in Patients With Relapsed
FX06
go.drugbank.com/drugs/DB05685InvestigationalFX06 is a naturally occurring peptide derived from the neo-N-terminus of fibrin (Bbeta(15-42)). It prevents leukocyte migration through the gap junctions of endothelial cells. FX06 has proven safe in acute and subchronic toxicological st...